{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-044416","form_type":"8-K","ticker":"INGN","cik":"0001294133","company_name":"Inogen Inc","filed_at":"2024-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.753857+00:00","generated_at":"2026-06-03T22:49:56.380097+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Inogen EVP R&D & Chief Medical Officer Stanislav Glezer to depart by May 3, 2024","bullets":["Mutual separation of Dr. Stanislav Glezer, EVP R&D and Chief Medical Officer, effective on or before May 3, 2024.","Company expects to enter a separation agreement with benefits consistent with his existing 2021 severance agreement.","No successor named; disclosure of separation agreement terms to be filed later.","Glezer was responsible for R&D and clinical strategy; departure leaves a key leadership gap."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-044416","json":"https://secwatch.observer/filing/0000950170-24-044416.json","markdown":"https://secwatch.observer/filing/0000950170-24-044416.md","text":"https://secwatch.observer/filing/0000950170-24-044416.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1294133/000095017024044416/0000950170-24-044416-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1294133/000095017024044416/ingn-20240411.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:49:56.380097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad647523fe","claim":"Stanislav Glezer departed as Executive Vice President, R&D and Chief Medical Officer at Inogen Inc.","evidence_excerpt":"On April 11, 2024, Inogen, Inc. (the “Company”) and Dr. Stanislav Glezer, Executive Vice President, R&D and Chief Medical Officer of the Company, mutually determined that Dr. Glezer would separate from the Company on or before May 3, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1294133/000095017024044416/0000950170-24-044416-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Executive Vice President, R&D and Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}